|
AMS Biotechnology
triple negative breast cancer Triple Negative Breast Cancer, supplied by AMS Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/tissue+immunostaining/10__1158_slash_1535___7163__mct___24___0588-98-75-82?v=AMS+Biotechnology Average 96 stars, based on 1 article reviews
triple negative breast cancer - by Bioz Stars,
2026-06
96/100 stars
|
Buy from Supplier |
|
Danaher Inc
inos ![]() Inos, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/tissue+immunostaining/pmc10363593-85-10-12?v=Danaher+Inc Average 99 stars, based on 1 article reviews
inos - by Bioz Stars,
2026-06
99/100 stars
|
Buy from Supplier |
|
Leuze electronic
clear lipid-exchanged acrylamide-hybridized rigid imaging/immunostaining/ in situ -hybridization-compatible tissue hydrogel ![]() Clear Lipid Exchanged Acrylamide Hybridized Rigid Imaging/Immunostaining/ In Situ Hybridization Compatible Tissue Hydrogel, supplied by Leuze electronic, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/tissue+immunostaining/pmc10406256-20-54-63?v=Leuze+electronic Average 90 stars, based on 1 article reviews
clear lipid-exchanged acrylamide-hybridized rigid imaging/immunostaining/ in situ -hybridization-compatible tissue hydrogel - by Bioz Stars,
2026-06
90/100 stars
|
Buy from Supplier |
|
College of American Pathologists
immunostained tissue sections ![]() Immunostained Tissue Sections, supplied by College of American Pathologists, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/tissue+immunostaining/pmc03311439-205-9-15?v=College+of+American+Pathologists Average 90 stars, based on 1 article reviews
immunostained tissue sections - by Bioz Stars,
2026-06
90/100 stars
|
Buy from Supplier |
|
ABclonal Biotechnology
immunostaining tissue sections kit ![]() Immunostaining Tissue Sections Kit, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/tissue+immunostaining/pmc08878216-185-12-21?v=ABclonal+Biotechnology Average 90 stars, based on 1 article reviews
immunostaining tissue sections kit - by Bioz Stars,
2026-06
90/100 stars
|
Buy from Supplier |
|
College of American Pathologists
microvessels in immunostained tissue sections ![]() Microvessels In Immunostained Tissue Sections, supplied by College of American Pathologists, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/tissue+immunostaining/pm26452314-23-13-1?v=College+of+American+Pathologists Average 90 stars, based on 1 article reviews
microvessels in immunostained tissue sections - by Bioz Stars,
2026-06
90/100 stars
|
Buy from Supplier |
|
3DHistech ltd
immunostained tissue microarray slides ![]() Immunostained Tissue Microarray Slides, supplied by 3DHistech ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/tissue+immunostaining/pm27075916-94-2-19?v=3DHistech+ltd Average 90 stars, based on 1 article reviews
immunostained tissue microarray slides - by Bioz Stars,
2026-06
90/100 stars
|
Buy from Supplier |
Image Search Results
Journal: Genes & Diseases
Article Title: FTO-mediated m6A modification alleviates autoimmune uveitis by regulating microglia phenotypes via the GPC4/TLR4/NF-κB signaling axis
doi: 10.1016/j.gendis.2022.09.008
Figure Lengend Snippet: Downregulated FTO was involved in microglia-elicited inflammation and migration in vitro . ( A , B ) RT-qPCR and Western blot for detecting the expression of iNOS, TNFα, and IL6 with or without LPS + IFN-γ treatment for 24 h ( n = 3). ( C ) Griess assay for detecting NO production in the supernatant with or without LPS + IFN-γ treatment for 24 h ( n = 3). ( D ) Transwell images and corresponding quantifications in the control group and the LPS + IFN-γ group ( n = 3). Scale bar, 100 μm. ( E ) Representative photomicrographs of the wound-healing assay performed on HMC3 cells before and after scratching. ( F ) The overall m 6 A% level of the control group and the LPS + IFN-γ group ( n = 3). ( G ) RT-qPCR for testing the relative mRNA expression of m 6 A methylase, demethylase, and readers in the control group and the LPS + IFN-γ group ( n = 3). ( H ) FTO protein expression in the control group and the LPS + IFN-γ group ( n = 3). Values are analyzed using the unpaired Student's t -test. ∗ P < 0.05, ∗∗ P < 0.01.
Article Snippet: The primary antibodies used in this study were as follows:
Techniques: Migration, In Vitro, Quantitative RT-PCR, Western Blot, Expressing, Griess Assay, Control, Wound Healing Assay
Journal: Genes & Diseases
Article Title: FTO-mediated m6A modification alleviates autoimmune uveitis by regulating microglia phenotypes via the GPC4/TLR4/NF-κB signaling axis
doi: 10.1016/j.gendis.2022.09.008
Figure Lengend Snippet: FTO knockdown upregulated inflammation and promoted microglial migration. ( A , B ) RT-qPCR and Western blot for determining FTO knockdown efficiency ( n = 3, unpaired Student's t -test). ( C ) Percentage of m 6 A content of the total RNA in the vehicle group and the shFTO group ( n = 3, unpaired Student's t -test). ( D ) CCK-8 assay for determining the proliferation of the vehicle and shFTO groups ( n = 3; unpaired Student's t -test). ( E , F ) The mRNA and protein levels of iNOS, TNFα, and IL6 in the vehicle- and shFTO-treated cells with or without LPS + IFN-γ stimulation ( n = 3; one-way ANOVA). ( G ) ELISAs for testing TNFα expression in the vehicle- or shFTO-treated cells with or without LPS + IFN-γ stimulation ( n = 3; one-way ANOVA). ( H ) Transwell images and corresponding quantifications of the vehicle group, vehicle + LPS&IFN-γ group, shFTO group, and shFTO + LPS&IFN-γ group ( n = 3; one-way ANOVA). ( I ) Representative images of the wound-healing assay performed in the vehicle group, vehicle + LPS&IFN-γ group, shFTO group, and shFTO + LPS&IFN-γ group ( n = 3; one-way ANOVA). ∗ P < 0.05, ∗∗ P < 0.01.
Article Snippet: The primary antibodies used in this study were as follows:
Techniques: Knockdown, Migration, Quantitative RT-PCR, Western Blot, CCK-8 Assay, Expressing, Wound Healing Assay
Journal: Genes & Diseases
Article Title: FTO-mediated m6A modification alleviates autoimmune uveitis by regulating microglia phenotypes via the GPC4/TLR4/NF-κB signaling axis
doi: 10.1016/j.gendis.2022.09.008
Figure Lengend Snippet: GPC4 knockdown reversed the effects of FTO on microglia. ( A , B ) RT-qPCR and Western blot for detecting GPC4 expression in the FTO-deficient HMC3 cells transfected with vehicle lentivirus, shGPC4-1, shGPC4-2, or shGPC4-3 lentivirus. ( C , D ) RT-qPCR and Western blot for showing the expression of iNOS, TNFα, and IL6 in vehicle 1 (corresponding to shFTO) +LPS&IFN-γ, shFTO + LPS&IFN-γ, shFTO + shGPC4+LPS&IFN-γ, and shFTO + vehicle 2 (corresponding to shGPC4) +LPS&IFN-γ groups. ( E , F ) CXCL10 mRNA and protein expression in different groups with the abovementioned stimulation. ( G ) The number of human CD4 + T cells that migrated into lower HMC3 cells in the abovementioned groups. ( H ) Expression levels of key proteins involved in the TLR4 pathway (TLR4, CD14, and CXCL10) in the abovementioned groups ( n = 3). Values are analyzed using the one-way ANOVA. ∗ P < 0.05; ∗∗ P < 0.01.
Article Snippet: The primary antibodies used in this study were as follows:
Techniques: Knockdown, Quantitative RT-PCR, Western Blot, Expressing, Transfection
Journal: Genes & Diseases
Article Title: FTO-mediated m6A modification alleviates autoimmune uveitis by regulating microglia phenotypes via the GPC4/TLR4/NF-κB signaling axis
doi: 10.1016/j.gendis.2022.09.008
Figure Lengend Snippet: FTO inhibition aggravated EAU progression in vivo . ( A ) Retinal FTO mRNA and protein expression in the FB23-2-treated mice and the PBS + DMSO-treated mice ( n = 3). ( B ) Experimental flowchart describing the modeling process and drug injection. ( C ) Representative images and quantification of the ocular anterior chamber (upper) and eyeball sections (lower) ( n = 5). Black arrows indicate inflammatory cells. Red arrows indicate conjunctival or ciliary hyperemia, or vasculitis. White arrows indicate posterior synechiae, or retinal folds. Scale bar, 100 μm. ( D , E ) RT-qPCR and Western blot for showing the expression levels of iNOS, TNFα, and IL6 in the EAU + vehicle and EAU + FB23-2 groups ( n = 3). ( F ) Protein expression levels of GPC4, TLR4, p-p65, and p65 in the EAU + vehicle and EAU + FB23-2 groups ( n = 3). Values are analyzed using the unpaired Student's t -test. ∗ P < 0.05; ∗∗ P < 0.01. ( G ) Graphical summary of this study.
Article Snippet: The primary antibodies used in this study were as follows:
Techniques: Inhibition, In Vivo, Expressing, Injection, Quantitative RT-PCR, Western Blot